MFDS
- Marketing authorisation holder: GLAXOSMITHKLINE
- Status: likely_approved
🇰🇷 Blujepa in South Korea
Blujepa (GEPOTIDACIN) regulatory status in South Korea.
Marketing authorisation
Blujepa in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Infectious Disease approved in South Korea
Frequently asked questions
Is Blujepa approved in South Korea?
Yes. MFDS has authorised it.
Who is the marketing authorisation holder for Blujepa in South Korea?
GLAXOSMITHKLINE holds the South Korean marketing authorisation.